Hutchmed announces continued inclusion of Orpathys in the National Reimbursement Drug List in China at current terms: Hong Kong, Shanghai Saturday, November 30, 2024, 16:00 Hrs [I ...
EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in ...